Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9564637 | 0.87 | LMNA (0.68) | LMNACYP2D6L3MBTL1ADRB2ADRB1 | |
| SCHEMBL421712 | 0.83 | LMNA (0.63) | LMNACYP2D6L3MBTL1ADRB2ADRB1 | |
| SCHEMBL738552 | 0.79 | LMNA (0.59) | LMNACYP2D6L3MBTL1ADRB2ADRB1 | |
| SCHEMBL551186 | 0.79 | LMNA (0.59) | LMNACYP2D6L3MBTL1ADRB2ADRB1 | |
| SCHEMBL12869056 | 0.79 | LMNA (0.70) | LMNACYP2D6L3MBTL1ADRB2ADRB1 | |
| SCHEMBL8187180 | 0.79 | LMNA (0.70) | LMNACYP2D6L3MBTL1ADRB2ADRB1 | |
| SCHEMBL8548126 | 0.78 | LMNA (0.63) | LMNACYP2D6L3MBTL1ADRB2ADRB1 | |
| SCHEMBL267463 | 0.78 | LMNA (0.68) | LMNACYP2D6L3MBTL1ADRB2ADRB1 | |
| SCHEMBL345402 | 0.78 | LMNA (0.68) | LMNACYP2D6L3MBTL1ADRB2ADRB1 | |
| SCHEMBL7688616 | 0.78 | LMNA (0.56) | LMNACYP2D6L3MBTL1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888118-A1 | STABILIZED POLYPEPTIDE FORMULATIONS | NOVO NORDISK A/S (DK) | 2008-02-20 | — | — | EP | claimed |
| WO-2006125763-A1 | STABILIZED POLYPEPTIDE FORMULATIONS | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | claimed |
| WO-2023212193-A1 | MICRO-DYSTROPHIN FOR HEART PROTECTION | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-4251187-A2 | TUMOR-SPECIFIC CLEAVABLE LINKERS | Xilio Development, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4126247-A1 | MASKED IL-2 CYTOKINES AND THEIR CLEAVAGE PRODUCTS | Xilio Development, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126249-A1 | MASKED IL-12 CYTOKINES AND THEIR CLEAVAGE PRODUCTS | Xilio Development, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022115865-A2 | TUMOR-SPECIFIC CLEAVABLE LINKERS | Xilio Development, Inc. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2021202675-A1 | MASKED IL-2 CYTOKINES AND THEIR CLEAVAGE PRODUCTS | Xilio Development, Inc. (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021202678-A1 | MASKED IL-12 CYTOKINES AND THEIR CLEAVAGE PRODUCTS | Xilio Development, Inc. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3423481-A1 | GLP-1 DERIVATIVES AND USES THEREOF | Novo Nordisk A/S (DK) | 2019-01-09 | — | — | EP | disclosed |
| EP-3233898-A1 | GLP-1 DERIVATIVES AND USES THEREOF | Novo Nordisk A/S (DK) | 2017-10-25 | — | — | EP | disclosed |
| WO-2007039140-A1 | GLP-1 ( GLUCAGON-LIKE PEPTIDE-1 ) FUSION POLYPEPTIDES WITH INCREASED PEPTIDASE RESISTANCE | BIOCOMPATIBLES UK LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
| EP-1765408-A2 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006128497-A1 | PHARMACEUTICAL FORMULATION OF FACTOR XI | NOVO NORDISK A/S (DK) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006125763-A1 | STABILIZED POLYPEPTIDE FORMULATIONS | NOVO NORDISK A/S (DK) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006122982-A1 | NEW POLY(ETHYLENE GLYCOL) DERIVATIVES AND PROCESS FOR THEIR COUPLING TO PROTEINS | NOVO NORDISK HEALTH CARE AG (DK) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006097521-A1 | PEGYLATED SINGLE-CHAIN INSULIN | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| EP-1687020-A1 | THERAPEUTIC USE OF FACTOR XI | Novo Nordisk Health Care AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006005667-A2 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK A/S (DK) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005049070-A1 | THERAPEUTIC USE OF FACTOR XI | NOVO NORDISK HEALTH CARE AG (CH) | 2005-06-02 | — | — | WO | disclosed |